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The present study was designed to examine the interaction of
the purified platelet glycoprotein Ib-IlIa complex (GP Ib-IlIa
or integrin aIlIbf3) and the individual subunits of the complex
with immobilized fibrinogen. Although 125I-GP Ib-IlIa binding
to fibrinogen immobilized on Sepharose was specific, this inter-
action exhibited properties distinct from those of reversible
fibrinogen binding to platelets: 125I-GP Ib-IlIa binding
appeared irreversible, but non-covalent, Ca2+-independent, and
was inhibited only weakly, or not at all, by the anti-(GP
Ilb-Illa) monoclonal antibodies lOE5 and 7E3 and synthetic
peptides from known platelet-binding domains of fibrinogen.
Reversibly dissociated GP Ilb or GP Illa subunits inhibited
INTRODUCTION
The glycoprotein Ilb-Illa complex (GP Ilb-IlIa) is a Ca`-
dependent heterodimer [1-3] on the platelet surface that binds to
fibrinogen and other adhesive proteins, thereby mediating platelet
aggregation [4-6] and adhesion to the subendothelium [7,8]. The
heterodimer consists of GP Ilb (Mr = 136000 nonreduced) and
GP Illa (Mr = 95000 nonreduced). [GP Ilb is also referred to as
the a-subunit, and GP Illa is referred to as the ,-subunit. GP Ilb
is composed of two disulphide-linked subunits: a heavy chain of
120 kDa, formerly called GP IIb., and a light chain of - 23 kDa
formerly called GP JIba. GP Illa is a single polypeptide of
- 95 kDa.] Glycoprotein lb-Illa (or integrin aIIb/13) is a member
of a large family of adhesion receptors termed integrins, which
are found on diverse cell types (for reviews, see [9,10]).
One especially well characterized aspect of fibrinogen's in-
teraction with GP Ilb-Illa is the reversible phase of soluble
fibrinogen binding to activated platelets, which is believed to
initiate platelet aggregation. Several binding sites likely to
mediate this phase have been identified on fibrinogen and on GP
Jib-Illa. On fibrinogen, these sites include a 10-12-amino acid
sequence at the C-terminus of the fibrinogen y-chain [11], termed
the L1O or H12 peptide respectively [12] (residues 402- or
400-411) and the Arg-Gly-Asp (RGD) sequence in positions
95-97 and 572-574 of the fibrinogen a-chain [13-15]. Sites on GP
Ilb-Illa that may recognize these fibrinogen peptides include
residues 296-306 on GP Ilb [16] and 109-171 [17], 211-222 [18],
or both, on GP Illa.
Under some circumstances, the interaction of platelets with
125I-GP Ilb-Illa binding to immobilized fibrinogen and bound
directly to the fibrinogen. However, these subunits did not bind
to peptides derived from known platelet-binding domains
within the fibrinogen a- and y-chains, although the GP Ilb-Illa
complex did. These results show that the complexed form of
full-length GP Ilb and GP Illa is required for binding to these
synthetic peptides, but not necessarily for binding to
immobilized fibrinogen. Thus GP Ilb-Illa can bind to
immobilized fibrinogen by a distinct mechanism that appears to
involve novel binding sites on each subunit of the GP Ib-Illa
complex and on fibrinogen.
fibrinogen displays properties that are less well understood.
Examples include the apparently irreversible, but non-covalent,
binding of 'l25-fibrinogen to activated platelets after extended
incubations [19,20], the partially irreversible binding of platelets
to fibrin immobilized in a clot [21], and the adhesion and
subsequently irreversible spreading of resting platelets on
immobilized fibrinogen through a GP Ib-IlIa-dependent mech-
anism [22]. Structural differences can be detected in fibrin(ogen)
immobilized in a clot [23,24], bound to the platelet surface [25],
or adhering to an artificial surface [26] (e.g. as neoepitope
exposure), which may be responsible for some of these
observations.
To gain additional insight into the interaction ofGP lib-Illa
with immobilized fibrinogen, we investigated the ability of GP
Ilb-illa and its reversibly dissociated subunits to bind to
fibrinogen immobilized on Sepharose. Both the GP Ilb-Illa
complex and each subunit of the complex were found to bind to
immobilzed fibrinogen. However, the properties of this binding
suggest that it is mediated by sites on GP Ib-Illa and fibrinogen




Fibrinogen was purified from human plasma by the glycine
precipitation procedure ofKazal et al. [27], modified as previously
described [28]. Purified fibrinogen was stored in a buffer of
50 mM Tris, 0.1 M NaCl and 0.02% NaN3, pH 7.4, at -80 'C.
Abbreviations used: GP llb-lila, glycoprotein llb-lIla complex; C12E8, hexa(ethylene glycol) mono-n-decyl ether; H12, the dodecapeptide from the
C-terminus of the fibrinogen y-chain with the sequence His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val; L10, the decapeptide from the C-terminus
of the fibrinogen y-chain, i.e., Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val; IPTG, isopropyl fl-D-thiogalactopyranoside; Me2SO, dimethyl sulphoxide.
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Glycoprotein lib-lila complex purification
Glycoprotein lb-Illa was purified from outdated human
platelets by the method of Fitzgerald et al. [29] with modifications
as previously described [30]. The purified GP Ilb-Illa complex
was stored at -80 'C in a buffer containing 20 mM Tris,
150mM NaCl, 1 mM CaCl2, 0.1°h Triton X-00 and 0.05%0
NaN, pH 7.4 (Buffer A).
Reversible dissociation of glycoprotein lb-llla
To form reversibly dissociated subunits, i.e. subunits that retained
the ability to reform the heterodimer complex, GP Ilb-Illa was
dissociated by the method of Steiner et al. [30]. Unlabelled or
1251-labelled GP Ilb-Illa was diluted in half with a buffer
comprising 20 mM Tris, 100 mM NaCl, 0.05 % Triton X-100,
0.05 %1 NaN, and 1 mM EGTA (pH 9.0 at room temperature),
incubated in a glass test tube at 37 °C for 5-6 min, and
immediately cooled to 4 'C. If the glycoprotein was to be used as
a mixture of dissociated subunits, CaCl2 (5 mM final concn.) was
added to the 4 'C solution, followed by titration to pH 7.3.
H.p.l.c. separation of reversibly dissociated glycoprotein llb and
Ilia subunits
To obtain h.p.l.c.-separated GP IIb and GP Illa subunits, the
mixture of reversibly dissociated GP Ilb and GP Illa was cooled
to 4 'C and HCl was added to return the pH to 7.2-7.3. The
subunits were immediately loaded on to a 300 mm x 7.5 mm Bio-
Sil TSK-400 h.p.l.c. column (Bio-Rad, Richmond, CA, U.S.A.)
attached to a Beckman model-l lOA h.p.l.c. pump at room
temperature [31]. The column was pre-equilibrated for several
weeks with a buffer comprising 20 mM Tris, 100 mM NaCl,
0.05 Go Triton X-l00 and 0.05 0 NaN, pH 7.2, such that the
A280 of the column input and output were identical, and run at
0.5 ml/min. Fractions were collected every 6 min (3 ml). Each
fraction was immediately cooled to 4 'C and 2 mM CaCi, was
added. To locate and pool subunits, aliquots of each fraction
were examined on silver-stained [32] 7.5 0 polyacrylamide
minigels (Bio-Rad). Pooled fractions of h.p.l.c.-separated GP
Ilb and GP Illa were concentrated 8-10-fold by ultrafiltration
(Amicon Concentrator with a YM 30 membrane, Amicon Corp.,
Danvers, MA, U.S.A.). For control samples, buffer alone was
concentrated to the same extent. In some experiments, h.p.l.c.-
separated GP Ilb amd GP Illa were labelled with 1251 while
attached to DEAE-Sephacel, as described below. Because the
condition of the h.p.l.c. column changed with time, different
degrees of separation of GP Ilb and GP Illa were achieved in
different experiments.
Irreversible dissociation of glycoprotein lb-Illa
1251-GP Ilb-Illa (labelled as described below) was diluted in half
with a buffer composed of 20 mM Tris, 100 mM NaCl, 0.05 %/0
Triton X-l00, 0.05 %h NaN, and 2.4 mM EDTA (pH 8.4 at
37 °C), incubated for 110 min at 37 'C and cooled on ice to 4 'C.
CaC12 (7 mM) was re-added, and the pH was adjusted to 7.2.
Glycoprotein Ilb and GP Illa dissociated under these conditions
do not retain the ability to reform heterodimer complexes under
any known conditions [30]. As a control, the 125I-GP Ilb-Illa
complex was diluted into a buffer that had the same final
concentration of components as above (i.e., 2.4 mM EDTA and
Labelling glycoprotein llb-lila or the dissociated subunits with 1251
Glycoprotein Ib-Illa was labelled with 1251 in one of two
methods designed to avoid labelled Triton X- 100. In one method,
GP Ilb-Illa or the h.p.l.c.-purified subunits were diluted with
Buffer A lacking NaCl to decrease the NaCl concentration to
50 mM. The glycoprotein was attached to a 0.4 ml column of
DEAE-Sephacel. The column was washed with a buffer
composed of 20 mM Tris, 50 mM NaCl, the detergent
hexa(ethylene glycol) mono-n-decyl ether (C12E8; 0.5 mg/ml)
1 mM CaCl2, and 0.020°/0 NaN, (Buffer C) to remove the Triton
X-100. The glycoprotein was labelled while attached to the
column by applying 490 ,ul of Buffer C containing chloramine T
(0.5 mg/ml) with 10 ,ul of 1125 (1 mCi). The column was washed
with 0.5 ml of Buffer C containing sodium metabisulphite
(0.49 mg/ml) to stop the iodination reaction. The free 1251 was
removed by washing the column with 10 ml of Buffer A with
50 mM NaCl. The glycoprotein was eluted with Buffer A con-
taining 500 mM NaCl and stored at -80 'C. In the second
method, GP Ilb-Illa in Buffer A was incubated with 1251
(1-2 mCi) and two lodo-Beads as described [28], diluted 10-fold
with Buffer A without Triton X-100 (Buffer B) and separated
from free 1251 and unbound Triton X-100 by gel filtration
through a PD 10 column (Pharmacia) equilibrated with Buffer B.
Fractions containing I1-GP Ilb-Illa were pooled, and 0.1 °C,o
Triton X-100 was re-added. The specific activity of the glyco-
protein was determined by the protein precipitation microassay
of Peterson [33], using BSA as the standard, and by 1251
radioactivity measurements. The 1251-GP Ilb-Illa complex that
was labelled by either procedure remained as a complex with a
'native' conformation, as demonstrated by the resistance of the
heavy-chain GP Ilb to hydrolysis by thrombin [34,35].
Coupling proteins or peptides to Sepharose
Proteins [fibrinogen, ,J-galactosidase (Worthington) or
ovalbumin, transferrin, and immunoglobulin (from Sigma),
glycine, at a concentration of 1 mg/ml of Sepharose, or Gly-Arg-
Gly-Asp-Ser-Pro-Lys (GRGDSPK) (Biosearch, San Rafael,
CA, U.S.A.; pre-extracted with ethyl acetate) at 6 mg/ml of
Sepharose] were coupled to CNBr-activated Sepharose 4B
(Pharmacia) according to the manufacturer's instructions. Gly-
cine was used to block sites that had not reacted. The
coupled Sepharose was resuspended in an equal volume of
0.02 M Hepes/0.1 0O Triton X-100/0.1 M NaCl, pH 7.35, and
stored at -4 OC. The peptide Cys-Tyr-Gly-His-His-Leu-Gly-
Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val (CYGHHLGGAKQAGDV)
(Biosearch) was coupled by a stable sulphur-carbon bond via the
cysteine residue to activated thiol-Sepharose 4B (Sigma)
premodified with 1,6-bis(maleimido)hexane (Pierce) [36].
Binding assay
Assays to measure the binding of 125I-GP Ilb-Illa complex or
subunits to proteins or peptides coupled to Sepharose were
carried out as follows. 125I-labelled glycoprotein (10-20 a10) was
mixed with or without excess unlabelled protein or buffer in
0.5 ml Eppendorf test tubes (Brinkman Instruments Co.,
Westbury, NY, U.S.A.), in order to determine non-specific and
total binding respectively or to examine the effects of various
proteins on 2511-glycoprotein binding. Specific binding is defined
as total minus non-specific 1251-glycoprotein binding. Crystallized
BSA (Figure 1 below) was from Sigma. Binding was initiated by
addition of the protein-Sepharose (20 ,ll). The final volume was
250 ul unless otherwise indicated. Incubations were generally
7 mM CaCl2). performed for 3 h at 4 'C, except as indicated in the Figure
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legends, with constant mixing on a Nutator (Clay Adams,
Parsippany, NJ, U.S.A.). The final buffer composition for a
typical binding experiment was approx. 15 mM Hepes,
2.5 mM CaCl2, 0.1 mM NaCl, 0.02 ,O NaN3, 0.1 0O Triton X-100
and 3 mM Tris, pH 7.35-7.4. In some instances 25 mM Tris was
used instead of Hepes, without apparent effect on the results.
Incubations involving reversibly or irreversibly dissociated but
unseparated 1251I-GP Ilb and 125I-GP Illa also contained EGTA
or EDTA from the added '25I-GP Ilb-Illa, as described above.
Thus, in the experiment with reversibly dissociated but
unseparated subunits, the final Ca2+ concentration was
- 2.7 mM and that ofEGTA was 0.02 mM. With the irreversibly
dissociated subunits, the final Ca2+ concentration in the binding
assay was - 2.8 mM and the EDTA concentration was
- 0.1 mM. In experiments with h.p.l.c.-separated subunits, the
EGTA was most likely removed during the h.p.l.c. step and the
final Ca2+ concentration in the binding assay was - 2.6 mM.
Protein-Sepharose was sedimented at 8370g for 1 min in a
Beckman Microfuge B (Beckman Instruments, Palo Alto, CA,
U.S.A.), resuspended briefly in 250,tl of an ice-cold buffer
consisting of 0.02 M Hepes, 3 mM CaCl2, 0.1 0° Triton X-100,
0.1 M NaCl and 0.02% NaN3, pH 7.35, and quickly re-
sedimented. The tips of the tubes containing the Sepharose
pellets with bound 125I-labelled protein were cut off, and the
radioactivity of each was quantified in a y-radiation counter.
SDS/PAGE and densitometry
125I-Labelled glycoproteins were electrophoresed on SDS/7.5 %/-
polyacrylamide gels under reducing conditions by the method of
Laemmli t37] as described in [35]. The 125I-labelled glycoproteins
were detected by autoradiography of dried gels at -80 °C, using
Kodax X-OMAT AR film with du Pont Cronex intensifying
screens. The intensity of bands on X-ray film was determined by
densitometry on a Hoefer instrument.
Platelet aggregation
Washed human platelets were prepared on the day of use from
drug-free donors as described [38] and the platelets were
resuspended in a Hepes/Tyrode's buffer (5.5 mM glucose,
0.14 M NaCl, 11.9 mM NaHCO3, 1.4 mM CaCl2, 0.5 mM
MgCl2, 2.7 mM KCl and 10 mM Hepes, pH 7.4) to a concen-
tration of 3.3 x 108/ml. Stirred platelets (450 ,ul) were pretreated
for 1 min at 37 °C with ,1-galactosidase (Cooper Biomedical,
Philadelphia, PA, U.S.A.), isopropyl /3-D-thiogalactopyranoside
(IPTG) (Sigma) or Hepes/Tyrode's Buffer (50 ,ul) before addition
of A23187 (0.12 ,uM) or thrombin (0.05 unit/ml). Aggregation
was measured in a Lumi aggregometer (Chrono-Log Corp.,
Havertown, PA, U.S.A.) by the turbidometric method originally
described by Born [39].
Calculations
In calculations to determine the molar amounts of glycoprotein
added or bound, we assumed Mr values of 240000 for GP
Ilb-Illa, 140000 for GP Ilb and 100000 for GP Illa [2].
RESULTS
Many of the experiments to characterize 1251-GP Ilb-IlIa com-
plex binding to immobilized fibrinogen were performed at 4 °C
because these conditions were necessary to maintain the glyco-
protein subunits in a dissociated state for latter experiments. A
time-course study carried out over 29 h at 4 °C indicated that the
binding of 125I-GP Ilb-IlIa (0.7 nM) to fibrinogen-Sepharose
approached maximal levels within 3 h (results not shown); this
time of incubation was therefore used in most experiments. The
binding of 125I-GP Ilb-IlIa was specific and saturable since it
was maximally inhibited by 100 fold excess unlabelled GP
Ilb-Illa or by soluble fibrinogen, but much less so by other
proteins such as transferrin, orosomucoid, or BSA (Figure 1).
Only a much higher concentration of BSA, representing a 4000-
fold molar excess over '25I-GP Ilb-Illa, was found to partially
suppress total, non-specific and specific binding. Unexpectedly,
/J-galactosidase, which was initially used as a control protein,
was found to strongly inhibit '25I-GP IIb-11Ia binding (Figure 1).
In a further test of specificity, 125I-GP Ilb-Illa (- 0.1 nM) was
added to several different proteins immobilized on Sepharose. If
the specific binding of 125I-GP Ilb-Illa to fibrinogen-Sepharose
is set at 1000% (0.73 fmol), binding to immobilized ,-
galactosidase was similar (98.9 0), whereas binding to beads
lacking protein (reactive sites blocked with glycine) was only
8.7%./ 25I-GP Ilb-Illa binding to other immobilized proteins
was also low: egg albumin, 28.2 o%; transferrin, 20.6 %; and IgG,
19.9 °.
Since ,-galactosidase bound to 125I-GP Ilb-Illa, inhibited 1251_
GP IIb-IIIa binding to fibrinogen (Figure 1) and contains the Arg-
Gly-Asp-Phe (RGDF) sequence [40] (see the Discussion section),
it was tested for its ability to inhibit platelet aggregation. When
aggregation of washed platelets was induced by the Ca2+
ionophore A23187 or thrombin, 83-galactosidase inhibited ag-
gregation in a concentration-dependent manner (IC50 - 0.5 ,uM).
This inhibition was not reversed by up to 16 mM IPTG, a potent
inhibitor of the enzymic activity of 8-galactosidase [41] (results
not shown), suggesting that /3-galactosidase inhibits aggregation
by a mechanism independent of its lactase activity, most likely by
blocking fibrinogen binding to GP Ilb-Illa on the platelet
surface.
The reversibility of 125I-GP Ilb-Illa binding to the immobilized
fibrinogen or /3-galactosidase was tested by incubating 125I-GP
Ilb-Illa (3 nM) with the immobilized proteins for 2 h, followed
by the addition of > 100-fold excess of unlabelled GP IIb-IIIa or
control buffer. Even after 1.5 h, 125I-GP IIb-IIIa binding to
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Figure 1 Selective inhibition of 125l-GP lIb-Illa binding to immobilized
fibrinogen by excess unlabelled proteins
Fibrinogen immobilized on Sepharose (equivalent of 0.1 cM fibrinogen) was incubated
withb251-GP fb-lila (- 0.5 nM) in the presence of various concentrations of unlabelled
proteins as indicated. Each point represents the average of two or more samples. Standard
errors are indicated.
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Figure 2 Binding of reversibly dissociated 1251-labelled GP lib and GP Illa
to immobilized fibrinogen
251-GP lb-lila was dissociated under 'reversible' conditions by treatment with EGTA, pH 8.0,
for 5 min at 37 °C (see the Experimental section). The temperature of the 1251-glycoprotein was
then decreased to 4 °C, excess Ca2+ was re-added, and the pH returned to 7.2. As a control,
1251-GP Ilb-lila was also diluted directly into the final buffer used above except at 4 °C initially
so as to maintain the heterodimer complex. The 1251-labelled glycoprotein preparations were
then incubated with fibrinogen-Sepharose for 3 h at 4 °C in the presence or absence of
0.21 1,M unlabelled GP lb-lila (final vol. 250 ul). Specific binding (total minus non-specific
binding) is shown and is the average of triplicate samples. Solid circles represent the binding
of 125I-GP Ilb-lila complex and open circles the binding of dissociated 1251-GP Ilb and 12511
GP Illa. Standard error bars are shown and calculated based on rules for propagation of error
as described in [54]. Note that the concentration of 1251-glycoprotein added (on the abscissa)
refers to the concentration of each individual glycoprotein species.
evidence of reversal, indicating a very strong interaction between
I25l-GP lIb-lila and the immobilized proteins. This interaction
was most likely non-covalent, however, since 1251-GP Ilb-Illa
could be dissociated from the immobilized fibrinogen with SDS.
'51-glycoprotein Ilb-Illa binding to the immobilized
fibrinogen could not be inhibited by many agents known to
inhibit fibrinogen binding to platelets [11,42-45] or to purified
GP IIb-Illa incorporated into phospholipid vesicles [28]. Fi-
brinogen normally binds to GP Ilb-Illa on activated platelets
with a Kd of - 150 aM [42]. The RGDS peptide from the
fibrinogen a-chain and the LIO peptide from the fibrinogen y-
chain block fibrinogen (0.1-0.2 ,uM) binding to platelets with Ki
values of 16,uM and 50,uM respectively, and the effect of both
pedtides together is additive [461. However, when immobilized
fibrinogen (representing 0.1 /tM fibrinogen) was incubated with
0.2 nM 125I-GP Ilb-IlIa in the presence of these peptides,
significant inhibition was not observed [100+ 2.00/ (SEM) 125J_
GP Ilb-Illa binding in the absence of peptides, 11 1 +2.6 0O with
0.5 mM RGDS, 91.1+4.1 O! with 0.5 mM L10 peptide and
122.3+ 6.9 0/0 with 0.5 mM of each peptide together]. Significant
inhibition was also not observed regardless of the incubation
time (1 or 3 h) or temperature (4 or 22°C) or if immobilized
fibrinogen was present at a 10-fold lower concentration. The
RGDS peptide was also ineffective in inhibiting 1251I-GP Ilb-Illa
binding to immobilized ,3-galactosidase. In addition, the anti-
(GP IIb-Illa) monoclonal antibodies lOE5 [44] and 7E3 [45] in
concentrations ranging from 30 to 3000-fold over that of 125J1
GPIlb-Illa were ineffective in inhibiting 1251-GPIlb-Illa binding
relative to control antibodies. However, lOE5 and 7E3 specifically
immunoprecipitated 125I-GP Ilb-Illa under similar conditions,
suggesting that the lack of immunoinhibition may be due to a
distinct mechanism of 125I-GP Ilb-Illa binding to the
immobilized fibrinogen. The calcium chelator EDTA (3.3 mM
with 1.7 mM CaCl2) also did not significantly inhibit 125I-GP
Ilb-Illa binding to the immobilized fibrinogen either at 4 °C or
at room temperature (results not shown). These experiments
were performed under conditions that would be expected to
maintain GP Ilb-Illa as a complex [30]. Thus 1251-GP Ilb-Illa
binding to fibrinogen immobilized on Sepharose appears to
occur in a Ca2+-, RGDS-, and L1O peptide-independent manner.
The sites on immobilized fibrinogen that mediate 1251-GP Ilb-Illa
binding may be distinct from, or involve more than, the RGDS-
and the LIO-peptide-containing sites. Conversely, distinct sites
on GP lIb-Illa other than those that bind to RGDS and the
decapeptide must also be involved.
To identify which glycoprotein subunit(s) mediate GP Ilb-Illa
binding to the immobilized fibrinogen, it was necessary to
determine whether 1251-GP Ilb-illa that was dissociated under
reversible conditions [30] retained fibrinogen-binding activity. As
Figure 2 shows, when 1251-GP Ilb-Illa was dissociated under
reversible conditions, the mixture of dissociated, but unseparated,
subunits bound as well to fibrinogen-Sepharose as did the 125J1
GP Ilb-Illa complex. The extent of dissociation of the GP
Ilb-Illa complex under these conditions is - 90 00 [30]. In
contrast, when the 1251-GP Ilb-Illa complex was dissociated so
that 1251I-GP Ilb and 1251-GP Illa were no longer able to reform
heterodimer complexes (i.e. under irreversible conditions), the
specific binding was greatly reduced (results not shown).
To examine whether the results presented in Figure 2 were
affected by an exchange between the dissociated '25I-labelled
glycoproteins and the added unlabelled GP Ilb-IlIa, the fol-
lowing experiment was performed. 1251-glycoprotein Ilb and 1251_
GP Illa formed under reversible conditions were incubated with
and without excess unlabelled GP Ilb-Illa under conditions of a
typical binding assay, and analysed by sedimentation through
sucrose gradients [2]. In both cases, the 125I-GP Ilb and 1251-GP
lla sedimented in positions characteristic of the dissociated
subunits, but not of the GP Ilb-Illa complex (results not
shown). Thus the possibility of significant levels of exchange
occurring between dissociated and complexed glycoprotein sub-
units under the conditions of these experiments is unlikely.
Because 125I-GP Ilb-Illa binding to the immobilized fibrinogen
was not inhibited by synthetic peptides from the putative platelet-
binding domains of fibrinogen or fibronectin, we examined the
ability of the 1251-labelled GP Ilb-Illa complex to bind directly
to similar peptides immobilized on Sepharose, as has been shown
for unlabelled platelet GP Ilb-IlIa [47,48]. Indeed, we found that
'25I-GP Ilb-Illa bound in a specific manner to an RGDS-
containing peptide or to a pentadecapeptide that contains H12,
the 12-amino-acid sequence of the C-terminus of the fibrinogen
y-chain (Table 1). This binding was specific in that it was
inhibited by an excess of related peptides in solution. However,
whereas a mixture of unseparated 125I-GP Ilb and 1251I-GP Illa
subunits that were dissociated under reversible conditions did not
bind in a specific manner to peptides containing either the RGD
or H12 sequence, the same preparation of dissociated 125I-GP Ilb
and 1251-GP Illa subunits did retain the ability to bind to the
immobilized fibrinogen (Table 1), in agreement with earlier
results.
Two approaches were used to determine which of the
dissociated subunits was responsible for the binding to
immobilized fibrinogen detected in Figure 2 and Table 1.
Dissociated GP Ilb and GP Illa subunits were separated from
one another by h.p.l.c. In the first approach, the direct binding
of1251-GP Ilb, GP Illa or the complex was detected by incubating
each with immobilized fibrinogen and eluting the bound
material with SDS/electrophoresis sample buffer, followed by
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Table 1 Reversibly dissociated glycoprotein subunits, in contrast with the complex, do not bind to immobilized adhesive peptides but do bind to immobilized
fibrinogen
The same preparation of 1251-GP Ilb-lila complex or reversibly dissociated 1251-GP Ilb and 1251-GP Illa subunits (4 x 10-13 mol of each species in 300 ,ul or 1.3 x 10-12 M) was incubated with
fibrinogen- or GRGDSPK-Sepharose. Approx. 9 x 10-13 mol (or 3 x 10-12 M) of reversibly dissociated 1251-GP llb and 1251-GP Illa subunits were incubated with Sepharose-CYGHHLGGAKQAGDV.
Binding to the immobilized fibrinogen or peptides was determined in the absence (total binding) or the presence (non-specific binding) or either free fibrinogen (2.35 uM), GRGDSP (0.25 mM)
or HHLGGAKQAGDV (0.33 mM) respectively. Data represent the mean (± S.E.M.) of triplicate determinations. Specific binding is total binding minus non-specific binding. S.E.M. values for specific-
binding values were calculated based on rules for propagation of error [54].
Immobilized fibrinogen Immobilized GRGDSPK Immobilized CYGHHLGGAKQAGDV
125I-GP lb-Illa 1251-Dissociated 1251-GP lb-Illa 1251-Dissociated 1251-GP lb-lIla 1251-Dissociated
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Figure 3 Direct binding of 1251-GP lIb-lila and h.p.l.c.-separated '251-GP lib
and 1251-GP lila to immobilized fibrinogen
Lanes 1-3, fibrinogen immobilized on Sepharose was incubated with 1251-GP lb-Illa complex
(26 fmol in 250 ,ul of total incubation volume) in the absence (lane 1) or presence of excess
unlabelled GP lb-Illa (1.5 ,IM, lane 2) or fibrinogen (1 ,uM, lane 3). Bound 1251-labelled
protein was eluted as described in the Experimental section and observed by autoradiography
of SDS/7.5%-polyacrylamide gels. Lanes 4-5, h.p.l.c.-purified GP llb (lane 4) and GP lila (lane
5) that were labelled with 1251 and used in subsequent experiments. Twice the volume of 1211_
GP llb relative to 1251-GP Illa was added per lane, or - 1.4 x 106 c.p.m. of each. Lanes 6-9,
fibrinogen-Sepharose was incubated with 1251-GP llb (18 fmol in 250 ,dl) in the absence (lane
6) or the presence of excess unlabelled GP lb-llila (3.3 uM, lane 7), fibrinogen (3.3 ,uM, lane
8) or orosomucoid (3.3,M, lane 9), and treated as in lanes 1-3 above. Lanes 10-13,
fibrinogen-Sepharose was incubated with 1251-GP Illa (21 fmol in 250 ul) in the absence (lane
10) or presence of excess unlabelled GP lb-Illa (3.3 ,tM, lane 11), fibrinogen (3.3 ,uM, lane
12), or orosomucoid (3.3 ,M, lane 13), and treated as in lanes 1-3 above. Note that although
the intensities of the bands can be compared within groups, they cannot necessarily be
compared between groups because the Figure was compiled from separate experiments and the
autoradiograms were exposed under optimal conditions for each group.
1-3 show the specific binding of '25I-GP IWb-Illa. Note that GP
Illa appears darker than the heavy chain of GP Ilb in lane 1,
because of the characteristically increased labelling of GP Illa
with 1251 [49]. The h.p.l.c.-separated 1251-GP Ilb and 1251-GP Illa
preparations, which appeared > 950% pure as judged by
densitometry, are shown in lanes 4 and 5. When '25I-GP Ilb was
incubated with immobilized fibrinogen, '25I-GP Ilb bound
specifically (lane 6), since its binding was inhibited by excess
unlabelled GP Ilb-Illa (lane 7) or fibrinogen (lane 8), but not by
orosomucoid (lane 9). More 125I-GP Illa was present than
expected in lane 6 and 9, based on the apparent purity of the 1251_
GP Ilb preparation. However, densitometric analyses of the
ratios of 125I-GP lIb to GP Illa in lanes 6 and 9 versus lanes 1-3
indicated that > 80% of the observed specific binding must have
been due to dissociated 125I-GP Ilb as opposed to a potentially
small amount of contaminating GP Ilb-Illa complex. Purified
125I-GP Illa also bound specifically to the fibrinogen-Sepharose
as demonstrated in lanes 11-13.
In the second approach, the ability of different concentrations
of the individual unlabelled subunits to inhibit 125I-GP Ilb-Illa
binding to the immobilized fibrinogen was compared with that of
unlabelled GP Ilb-Illa. Both subunits inhibited binding at
concentrations similar to that of GP Ilb-Illa, suggesting that
both subunits have fibrinogen-binding activity (results not
shown).
DISCUSSION
The results of the present study demonstrate that purified GP
Ilb-Illa and immobilized fibrinogen can bind to one another
with characteristics distinct from those of soluble reversible
fibrinogen binding to activated platelets. These distinct
characteristics include the inability of EDTA, anti-(GP IWb-Illa)
monoclonal antibodies or the RGDS or LIO peptides derived
from sequences within the fibrinogen ac- and y-chains to inhibit
1251-GP IWb-Illa binding to immobilized fibrinogen, the ap-
parently irreversible nature of this binding and the ability of the
dissociated GP Ilb and GP Illa subunits to bind to the fibrinogen.
These results suggest that the observed binding is mediated at
least in part by sites on GP 11-Illa and fibrinogen that are
separate from those that mediate reversible fibrinogen binding to
platelets.
The irreversible (or very slowly reversible), yet apparently non-
covalent, binding of 125I-GP IWb-Illa to immobilized fibrinogen
(or /3-galactosidase) observed here and in other studies with
intact platelets [19-22] could be explained in part by co-
operation between multiple binding sites on the immobilized
fibrinogen and GP IWb-Illa. At least some of these binding sites
must be separate from those previously described, however, for
the following reasons. First, excess unlabelled GP Ib-Illa and
fibrinogen, but not agents such as monoclonal antibody lOE5 or
EDTA, inhibited this binding. Second, the dissociated subunits
of GP Ib-Ilila bound to immobilized fibrinogen but not to
peptides derived from putative binding domains of fibrinogen.
Much evidence exists to show that when fibrinogen is converted
into fibrin [23,24], immobilized on some artifical surfaces [26], or
even bound to platelets [25], its conformation is altered such that
previously cryptic epitopes become exposed, and previously
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exposed sites may become inaccessible. It is possible that newly
exposed binding sites could co-operate with one another or with
previously described sites to cause high-affinity interactions with
distinct properties, as observed here. These properties are not
associated with all types of immobilized fibrinogen, however.
Fibrinogen immobilized on certain plastics has been shown to
bind activated platelets [50] or GP Ilb-Illa incorporated into
liposomes [51] in a peptide- and antibody-sensitive manner.
The separate GP Ilb and GP Illa subunits each appear to have
binding sites that recognize immobilized fibrinogen when gen-
erated under conditions known to maintain a certain degree of
conformational integrity, that is, when generated under con-
ditions previously determined to result in reversibly dissociated
subunits [30]. This binding activity is much diminished when the
subunits are formed under more harsh conditions. The subunits
generated under reversible conditions do not recognize im-
mobilized H12- and RGD-containing peptides, suggesting that
putative recognition sites within these subunits either are not
efficiently exposed, perhaps because of subunit folding, or do not
bind with high enough affinity unless the subunits are complexed.
The former possibility seems the most likely, since Gulino et al.
recently found that a fragment of GP lIb (amino acid residues
171-464) when expressed in and isolated from Escherichia coli,
bound to fibrinogen in a Ca2+-dependent manner and binding
was inhibited by RGD- and LIO-containing peptides [52].
Of additional interest was the finding that ,-galactosidase
bound to GP Ilb-Illa, inhibited GP Ilb-Illa binding to
fibrinogen and inhibited platelet aggregation. Although the
mechanism by which 8-galactosidase binds to GP Ilb-Illa is
unknown, it may in part be related to the RGDF sequence,
which is present in each of this tetramer's four identical subunits
[40]. If this sequence is functional when ,-galactosidase is soluble,
it may bind to platelet GP Ilb-Illa and inhibit aggregation, and
may bind to soluble 1251-GP Ilb-Illa, thereby causing a steric
inhibition of binding to immobilized fibrinogen. The finding that
the related RGDS sequence did not inhibit 1u2I-GP Ilb-Illa
binding to either immobilized /3-galactosidase or fibrinogen
suggests that either the RGD sequences are not operational in
the immobilized proteins, are in an altered conformation that
results in a very strong interaction with GP Ilb-Illa, and/or that
these sequences function in cooperation with other sites in the
immobilized proteins.
Whether the mechanism ofGP Ilb-IlIa binding to immobilized
fibrinogen observed here occurs under physiological or patho-
logical conditions or to fibrinogen coated on prosthetic surfaces
is currently unknown. However, our observations suggest that
alternative mechanisms of fibrin(ogen) binding to GP Ilb-Illa
are possible. Potentially relevant situations include the obser-
vation that a significant proportion of platelet binding to
'immobilized' fibrin clots is not inhibited by an anti-(GP Ilb-Illa)
monoclonal antibody [21]. Furthermore, Savage and Ruggeri
observed that platelet binding to immobilized fibrinogen,
although mediated by GP Ilb-lIla, does not require platelet
activation, and results in an apparently irreversible binding of
spread platelets to the fibrinogen [22], properties clearly distinct
from the reversible phase of soluble fibrinogen binding to
activated platelets. Finally, fibrinogen and fibrin protofibrils in
solution bind to activated platelets in an initially reversible and
subsequently irreversible manner that is not well understood
[19,20,53].
In summary, our results suggest, first, that each subunit of the
GP lib-Illa complex can bind to immobilized fibrinogen;
secondly, that the binding of GP Ilb-Illa by an RGDS- or y-
chain H 1 2-mediated mechanism appears to require the intact GP
Ilb-Illa complex as opposed to the dissociated full-length
subunits; and finally, that GP Ilb-Illa and the individual
subunits can bind to immobilized fibrinogen through a novel
mechanism, independent of the RGDS and y-chain H12 sites,
which may depend on the conformation of fibrinogen. The
additional binding sites on GP Ilb-Illa and fibrinogen may
contribute to platelet-fibrinogen interactions under specific cir-
cumstances.
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